RBC Raises J&J Price Target to $255 After 52% Stock Rally
RBC Capital maintained its Outperform rating on Johnson & Johnson and raised the price target from $240 to $255 following a 52% stock surge between May 2025 and February 2026. Johnson & Johnson's revenue grew 3.2% with improved margins, contributing to a $562.3 billion market capitalization and bolstered investor confidence.
1. Return to Double-Digit Growth
Johnson & Johnson reported a marked improvement in its top‐line performance during the last fiscal year, achieving a year‐over‐year revenue increase of 10.5%. This acceleration was driven primarily by strong demand for its immunology and cardiovascular drug franchises. Management emphasized that the oncology segment, boosted by the recent launch of two new antibody‐drug conjugates, is on track to become a $5 billion business by 2028, underpinned by ongoing clinical pipeline readouts and label expansions in multiple tumor types.
2. RBC Capital Affirms Outperform Rating
On February 3, 2026, RBC Capital reaffirmed its ‘Outperform’ recommendation for Johnson & Johnson and raised its 12‐month price target by 6.3%, reflecting enhanced visibility into the company’s medium-term growth trajectory. The upgrade follows management’s guidance for mid‐single‐digit organic revenue growth over the next three years and operating margin expansion of 150 basis points, supported by cost‐structure optimization and the phasing-in of higher-margin specialty products.
3. 52% Stock Surge Fueled by Innovation and Legal Progress
Between May 2025 and February 2026, Johnson & Johnson’s share price climbed by 52%, a rally attributed to three key drivers: a 3.2% uplift in total revenue, meaningful margin expansion of 120 basis points, and the resolution of legacy legal liabilities. The company’s successful defense in several high-profile litigation cases resulted in a cumulative reduction of potential settlements by over $2.3 billion, boosting investor confidence in the durability of free cash flow generation.
4. Robust Market Capitalization and Risk Management
With a market capitalization of approximately $562.3 billion, Johnson & Johnson remains one of the largest diversified healthcare companies globally. Trading volumes have remained elevated, averaging 1.3 million shares per day, as institutional investors increase allocations to defensive growth equities. The company’s proactive risk-management framework—highlighted by its establishment of a $3 billion litigation reserve and continuous portfolio rationalization—has reinforced its balance-sheet strength and ability to fund strategic M&A opportunities in high-growth therapeutic areas.